Sudeep Pharma Ltd

- Acquired a 20-acre land in Dahej for new manufacturing facility. - Phase one capex for Dahej site: ~INR 220 crores (includes land and development) for 25,000 tons capacity. - Infrastructure being built to support phase two, doubling capacity to 50,000 tons. - Long-term goal to scale plant to 100,000 tons for battery-grade iron phosphate. - Total expected capex to reach ~INR 500 crores over next few years. - Existing pilot plant producing 200 kgs/day; samples supplied to 36+ customers. - Capacity enhancement planned on existing food grade iron phosphate line to meet early demand before Dahej plant operational. - Greenfield capex of INR 150 crores for 51,200 MT capacity, with INR 120 crores spent by Sept '25; balance INR 20-30 crores to be spent by March '26. - Capex funded through internal accruals; debt levels expected to remain stable. - Expansion in Europe through acquisition of Nutrition Supplies and Services (NSS) to boost infant and clinical nutrition segment.

- FY '26 growth expected at approximately 26%, sustained for the full year. - Significant growth anticipated in Q3 FY '26, especially in the US market, post-tariff clarity. - NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area. - NSS capacity utilization currently ~35%, with plans to scale volumes notably by FY '27. - New Greenfield facility (51,200 metric tons capacity) expected commissioning Q4 FY '26; first meaningful production from this site expected in H2 FY '27 and predominantly FY '28. - Current overall manufacturing utilization near 50%, expected to increase with new capacity and approvals over next 2-3 years. - Direct sales approach in Europe and the US to improve volumes and margin realization by reducing distributor dependency. - Healthy project pipeline and global customer tie-ups to support sustained volume growth.

- Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S. tariff impacts and strong demand recovery. - The recently acquired NSS business, currently at ~35% capacity utilization, has a significant project pipeline expected to contribute meaningfully from FY27 and FY28. - The new greenfield manufacturing facility (51,200 MT capacity) is expected to be commissioned by Q4 FY26, supporting volume growth and higher-margin product introduction. - Capacity utilization currently at ~50%, with targets to ramp up production and revenues from new capacity post approvals starting FY27, leading to improved earnings. - Margins are expected to revert to historical averages (~63-64% gross margin; >35% EBITDA margin) as pass-through contracts normalize and scale benefits from sales and operational investments materialize. - Strategic investments in direct sales presence and supply chain optimization are expected to yield margin improvement over the next few quarters. - Overall, Sudeep Pharma anticipates sustainable long-term earnings growth supported by capacity expansion, market expansion, and R&D-driven product innovation.

- The company anticipates a strong Q3 FY26 due to delayed order book recognition in Q2, especially from the US market impacted by tariff uncertainties. - NSS, acquired in May 2025, has a significant project pipeline in Europe and global markets to expand its infant and clinical nutrition offerings. - NSS is currently operating at approximately 35% capacity utilization, with plans to scale up through leveraging Sudeep Pharma’s global customer base. - Campaign orders for large pharma and nutrition companies contribute significantly but are irregular, causing quarterly fluctuations in order volumes. - Customer procurement in specialty ingredients involves both monthly recurring orders and campaign-based large-volume orders. - The company expects order volumes and revenues to normalize and grow steadily in H2 FY26 and beyond as tariff impacts abate and new customer contracts ramp up.

- For the Greenfield capex (51,200 metric tons capacity), the project outlay is INR 150 crores. - Approximately INR 120 crores have been spent by September 2025; the remaining INR 20-30 crores will be spent by March 2026. - This remaining capex is expected to be funded through internal accruals. - The company expects debt levels to remain at current levels, implying no significant new debt is planned for this capex. - No mention of any planned equity fundraising was disclosed in the provided transcript. - Overall, current plans reflect funding the near-term capex largely through existing resources without additional debt or equity raise.